FUSION GENE OF KIF5B GENE AND RET GENE, AND METHOD

专利名称：FUSION GENE OF KIF5B GENE AND RET

GENE, AND METHOD FOR DETERMININGEFFECTIVENESS OF CANCER TREATMENTTARGETING FUSION GENE

发明人：KOHNO Takashi,TSUTA Koji申请号：EP12820601.8申请日：20120803公开号：EP2740742B1公开日：20180314

摘要：In order to identify a gene that can serve as an indicator for predicting theeffectiveness of a drug treatment of cancer and to provide a novel method for predictingthe effectiveness of a drug treatment targeting said gene, lung adenocarcinomas weresubjected to whole-transcriptome sequencing. As a result, in-frame fusion transcriptsbetween the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusionswere detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 outof 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealedknown activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusionswere found to be responsible mutations (driver mutations) for oncogenesis. Since saidgene fusions are considered to induce constitutive activation of RET tyrosine kinaseprotein, it was found that treatments with RET tyrosine kinase inhibitors are effective inpatients with detection of said gene fusions.

申请人：NAT CANCER CT

地址：JP

国籍：JP

代理机构：Cabinet Plasseraud

更多信息请下载全文后查看